Literature DB >> 25086336

Spectrum of muscular dystrophies associated with sarcolemmal-protein genetic defects.

Vincenzo Nigro1, Giulio Piluso2.   

Abstract

Muscular dystrophies are heterogeneous genetic disorders that share progressive muscle wasting. This may generate partial impairment of motility as well as a dramatic and fatal course. Less than 30 years ago, the identification of the genetic basis of Duchenne muscular dystrophy opened a new era. An explosion of new information on the mechanisms of disease was witnessed, with many thousands of publications and the characterization of dozens of other genetic forms. Genes mutated in muscular dystrophies encode proteins of the plasma membrane and extracellular matrix, several of which are part of the dystrophin-associated complex. Other gene products localize at the sarcomere and Z band, or are nuclear membrane components. In the present review, we focus on muscular dystrophies caused by defects that affect the sarcolemmal and sub-sarcolemmal proteins. We summarize the nature of each disease, the genetic cause, and the pathogenic pathways that may suggest future treatment options. We examine X-linked Duchenne and Becker muscular dystrophies and the autosomal recessive limb-girdle muscular dystrophies caused by mutations in genes encoding sarcolemmal proteins. The mechanism of muscle damage is reviewed starting from disarray of the shock-absorbing dystrophin-associated complex at the sarcolemma and activation of inflammatory response up to the final stages of fibrosis. We trace only a part of the biochemical, physiopathological and clinical aspects of muscular dystrophy to avoid a lengthy list of different and conflicting observations. We attempt to provide a critical synthesis of what we consider important aspects to better understand the disease. In our opinion, it is becoming ever more important to go back to the bedside to validate and then translate each proposed mechanism. This article is part of a Special Issue entitled: Neuromuscular Diseases: Pathology and Molecular Pathogenesis.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Duchenne muscular dystrophy; Dysferlin; Dystroglycan; Dystrophin; Sarcoglycan; limb-girdle muscular dystrophy

Mesh:

Substances:

Year:  2014        PMID: 25086336     DOI: 10.1016/j.bbadis.2014.07.023

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  21 in total

Review 1.  Muscular dystrophy in a dish: engineered human skeletal muscle mimetics for disease modeling and drug discovery.

Authors:  Alec S T Smith; Jennifer Davis; Gabsang Lee; David L Mack; Deok-Ho Kim
Journal:  Drug Discov Today       Date:  2016-04-22       Impact factor: 7.851

2.  Proceedings of the 2017 National Toxicology Program Satellite Symposium.

Authors:  Susan A Elmore; Famke Aeffner; Dinesh S Bangari; Torrie A Crabbs; Stacey Fossey; Shayne C Gad; Wanda M Haschek; Jessica S Hoane; Kyathanahalli Janardhan; Ramesh C Kovi; Gail Pearse; Lyn M Wancket; Erin M Quist
Journal:  Toxicol Pathol       Date:  2017-11-07       Impact factor: 1.902

3.  Muscular dystrophy in PTFR/cavin-1 null mice.

Authors:  Shi-Ying Ding; Libin Liu; Paul F Pilch
Journal:  JCI Insight       Date:  2017-03-09

Review 4.  Stem cell therapy for muscular dystrophies.

Authors:  Stefano Biressi; Antonio Filareto; Thomas A Rando
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

5.  Severe murine limb-girdle muscular dystrophy type 2C pathology is diminished by FTY720 treatment.

Authors:  Ahlke Heydemann
Journal:  Muscle Nerve       Date:  2017-03-26       Impact factor: 3.217

6.  Combinatorial therapeutic activation with heparin and AICAR stimulates additive effects on utrophin A expression in dystrophic muscles.

Authors:  Christine Péladeau; Aatika Ahmed; Adel Amirouche; Tara E Crawford Parks; Lucas M Bronicki; Vladimir Ljubicic; Jean-Marc Renaud; Bernard J Jasmin
Journal:  Hum Mol Genet       Date:  2015-10-22       Impact factor: 6.150

Review 7.  Duchenne and Becker Muscular Dystrophies: A Review of Animal Models, Clinical End Points, and Biomarker Quantification.

Authors:  Kristin Wilson; Crystal Faelan; Janet C Patterson-Kane; Daniel G Rudmann; Steven A Moore; Diane Frank; Jay Charleston; Jon Tinsley; G David Young; Anthony J Milici
Journal:  Toxicol Pathol       Date:  2017-10-03       Impact factor: 1.902

8.  Validation of a Muscle-Specific Tissue Image Analysis Tool for Quantitative Assessment of Dystrophin Staining in Frozen Muscle Biopsies.

Authors:  Famke Aeffner; Crystal Faelan; Steven A Moore; Alexander Moody; Joshua C Black; Jay S Charleston; Diane E Frank; Johannes Dworzak; J Kris Piper; Manish Ranjitkar; Kristin Wilson; Suzanne Kanaly; Daniel G Rudmann; Holger Lange; G David Young; Anthony J Milici
Journal:  Arch Pathol Lab Med       Date:  2018-08-31       Impact factor: 5.534

9.  Abnormal Skeletal Muscle Regeneration plus Mild Alterations in Mature Fiber Type Specification in Fktn-Deficient Dystroglycanopathy Muscular Dystrophy Mice.

Authors:  Steven J Foltz; Jill N Modi; Garrett A Melick; Marin I Abousaud; Junna Luan; Marisa J Fortunato; Aaron M Beedle
Journal:  PLoS One       Date:  2016-01-11       Impact factor: 3.240

10.  Influence of Botulinumtoxin A on the Expression of Adult MyHC Isoforms in the Masticatory Muscles in Dystrophin-Deficient Mice (Mdx-Mice).

Authors:  Ute Ulrike Botzenhart; Constantin Wegenstein; Teodor Todorov; Christiane Kunert-Keil
Journal:  Biomed Res Int       Date:  2016-08-07       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.